Technical Articles

This article focuses on the molecular characteristics and targeted therapeutic strategies of the KRAS G12D mutation, systematically elucidating the distribution patterns of RAS family gene mutations and their molecular mechanisms driving tumorigenesis. It provides an in-depth analysis of the challenges in drug development for KRAS G12D due to the lack of covalent binding sites and explores the novel approach of VHL-based PROTAC technology for targeted degradation of KRAS G12D.